PubMed Health⌕ Search

PubMed · 11182896

[High Resolution ECG Methods and Programmed Stimulation]

Abstract

There are not many "gates to death", but one of the most important is the sudden cardiac death. Therefore the exact knowledge of drug effects on the cardiac function, especially of arhythmogenic side effects are crucial during the development of a new compound. Hitherto expensive catheter experiments in anesthetized animals (dogs, pigs or monkeys) were necessary to evaluate drug effects on the intracardiac electrophysiological activity of all parts of the cardiac conduction system. Only these intracardiac stimulation and recording methods were suitable to measure drug effects on all parameters used in clinical electrophysiology. A suitable method, to replace at least partly these catheter experiments, was developed with a new epicardiac surface and stimulation technique (SST-ECG method: Stark et al, Basic Res. Cardio. 82, 437, 1987; Stark et al, J. Pharmacol. Meth. 21, 195, 1989) which received the prize of the Austrian government for "Alternative Methods to Animal Experiment" in 1988. With this method all parameters used in clinical electrophysiology can be evaluated in one isolated heart preparation and, thus, interactions with anesthetics and of the vegetative nervous system can be excluded. Due to the high resolution of this system, the common ECG-Parameters (PQ-, QT-time and heart rate) and the low amplitude signals (such as early atrial and His-bundle signals) can be detected continuously. Additionally, the refractory periods of all parts of the conduction system can be determined. It is further possible to evaluate hemodynamic parameters such as left ventricular contraction amplitude and coronary flow. A great advantage of the SST-ECG method is the minor scattering of the values measured, due to the elimination of effects of anesthetics and of the vegetative nervous system and the lack of problems with the electrode position. In the future, the evaluation of drug effects on the cardiac electrical activity will further need laboratory animals, but the number of experiments can be significantly reduced and in vivo experiments on anesthetized dogs, pigs or monkeys can mainly be replaced by in vitro experiments using isolated heart preparations of rats or guinea-pigs.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H. A. Tritthard, G. Stark, E. Hofer. 1990. [High Resolution ECG Methods and Programmed Stimulation]. https://pubmed.ncbi.nlm.nih.gov/11182896/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗